Article
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
International journal of hematology - 1 Apr 2012
Usuki Kensuke, Tojo Arinobu, Maeda Yasuhiro, Kobayashi Yukio, Matsuda Akira, Ohyashiki Kazuma, Nakaseko Chiaki, Kawaguchi Tatsuya, Tanaka Hideo, Miyamura Koichi, Miyazaki Yasushi, Okamoto Shinichiro, Oritani Kenji, Okada Masaya, Usui Noriko, Nagai Tadashi, Amagasaki Taro, Wanajo Aira, Naoe Tomoki
Abstract excerpt
Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.